Concepedia

Author

Dong‐Wan Kim

Seoul National University Hospital

Also Known As

D.W. KIM, Dong-Wan Kim, Dong‐Wan Kim

158

Publications

27.8K

Citations

60

H-Index

90

Concepts

All Affiliations

Seoul National University HospitalSeoul National UniversitySamsung Medical CenterYonsei UniversityAsan Medical Center
DK

About

Dong‐Wan Kim is an author at Seoul National University Hospital specializing in medicine, oncology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

28

45

7K

2

Engineering

10

10

515

3

Health Sciences

8

8

2.8K

4

Applied Physics

8

8

431

5

Allergy

1

1

36

Dong‐Wan Kim

×

126

Publications

27.4K

Citations

59

H-Index

YearCitations

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa,

New England Journal of Medicine

2013

3.4K

First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer

Benjamin Solomon, Tony Mok, Dong‐Wan Kim,

New England Journal of Medicine

2014

3.2K

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Darren A.E. Cross, Susan Ashton, Serban Ghiorghiu,

Cancer Discovery

2014

2.2K

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Pasi A. Jänne, James Chih‐Hsin Yang, Dong‐Wan Kim,

New England Journal of Medicine

2015

2.1K

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

Winette T.A. van der Graaf, Jean‐Yves Blay, Sant P. Chawla,

The Lancet

2012

2K

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne,

The Lancet Oncology

2016

1.1K

Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer

D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn,

New England Journal of Medicine

2018

945

Alectinib in Crizotinib-Refractory <i>ALK-</i>Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

Sai‐Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris,

Journal of Clinical Oncology

2015

578

Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component

James Chih‐Hsin Yang, Myung‐Ju Ahn, Dong‐Wan Kim,

Journal of Clinical Oncology

2017

563

Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study

Patrick A. Ott, Élena Elez, Sandrine Hiret,

Journal of Clinical Oncology

2017

531

Page 1